IPOs & Listings

Analysis

X-energy's IPO pricing 40% above the midpoint of its range, on zero operating reactors and an 18-month NRC review ahead, confirms that capital markets are pricing nuclear licensing optionality rather than cash flow. This creates a valuation reference point that compresses the discount rivals Oklo and NuScale trade at relative to their own pipelines, while simultaneously raising the bar for any subsequent advanced reactor IPO to clear without a named hyperscaler anchor deal of comparable scale.

Analysis

Victory Giant's 50% debut pop on a $2.6bn raise confirms that Hong Kong investors are willing to pay a significant premium for direct Nvidia supply chain exposure at a time when AI infrastructure demand is TSMC-confirmed and fabless order visibility is high. This validates the re-rating underway in PCB and substrate names globally, particularly those with concentrated AI customer books. The overhang question is whether the Shenzhen-listed A-share, already up fourfold, now faces arbitrage selling as the H-share discount closes.

Analysis

The executive order compresses regulatory timelines that have historically been the primary barrier to institutional capital entering psychedelics biotech. Oppenheimer's non-symbolic framing suggests sell-side coverage is about to expand, which pulls in crossover hedge funds that require analyst sponsorship before initiating positions. The near-term risk is that policy enthusiasm runs ahead of Phase 2/3 readouts; the sector has multiple binary clinical events in 2026 that could reverse any re-rating built on regulatory optionality rather than data.

Analysis

Blackstone's ability to exit Jersey Mike's at a premium to its 2023 entry validates its consumer PE playbook at a moment when PE exit markets remain constrained. A successful IPO increases Blackstone's carry realization in its current fund vintage and signals to LPs that consumer brand exits via public markets are viable again, which supports fundraising for BX's next consumer-focused vehicle.